Assessing and Advancing PBC Care: Monitoring, Risk Stratification, and Individualized Treatment Planning
Assessing and Advancing PBC Care: Monitoring, Risk Stratification, and Individualized Treatment Planning supports clinicians through education to improve PBC response assessment and individualized management.
Funder: Ipsen
Due Dates: November 13, 2026 (Submission) | December 4, 2026 (Notification) | May 2027 (Preferred launch)
Funding Amounts: Up to $300,000 from Ipsen; enduring activity must remain active for at least 12 months
Summary: Supports independent medical education to improve PBC treatment-response assessment, risk stratification, individualized management, and symptom recognition.
Key Information: Proposals must include a live symposium at the 2027 Digestive Disease Week congress and an enduring activity.
Description
Ipsen supports independent medical education addressing unmet educational needs in primary biliary cholangitis (PBC). Programs should improve clinicians’ ability to recognize inadequate treatment response, determine when management needs reassessment, and apply risk-stratification strategies to identify patients at risk of disease progression and guide longitudinal monitoring.
The program also prioritizes individualized management for patients who respond inadequately to, or cannot tolerate, current therapy through balanced consideration of available treatment options. Education should improve recognition and assessment of PBC-related symptoms, including pruritus and fatigue, and their impact on quality of life. The U.S.-focused initiative targets gastroenterologists, hepatologists, nurse practitioners, physician assistants, pharmacists, and nurses. The grantee independently designs and conducts the initiative, without Ipsen’s involvement or influence.
